BiotechTubeBiotechTube
Home/Pipeline/Soticlestat (TAK-935)

Soticlestat (TAK-935)

Epilepsy

Phase 3Active

Key Facts

Indication
Epilepsy
Phase
Phase 3
Status
Active
Company
Takeda Pharmaceutical

About Takeda Pharmaceutical

Founded in 1781, Takeda is a leading global biopharmaceutical company headquartered in Tokyo, Japan, with operations in over 80 countries. The company transformed through strategic acquisitions including Shire in 2019, building a diversified portfolio in oncology, rare diseases, neuroscience, and gastroenterology. Takeda focuses on developing breakthrough therapies while maintaining a strong commercial presence with blockbuster drugs generating billions in annual revenue.

View full company profile

Therapeutic Areas

OncologyRare DiseasesNeuroscienceGastroenterology

Other Epilepsy Drugs

DrugCompanyPhase
UCB4144UCBPhase 2
Keppra (levetiracetam)UCBApproved
NBI-921352Neurocrine BiosciencesPhase 2
Oxtellar XR®Supernus PharmaceuticalsApproved/Commercial
ADX71149Addex TherapeuticsPhase 2
Motpoly XR™Aucta PharmaceuticalsNot Specified (Likely Phase 3/NDA)
ADB-104Adolore BioTherapeuticsPre-clinical